Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the European Union for children with ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show ...
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announces the European Medicines Agency (EMA) marketing approval of the mylife(TM) YpsoPump® insulin pump for use with prefilled pump ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that Victoza® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts: 293-OR, 240-OR Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 185-OR and 187-OR Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th ...
Gothenburg, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Poster# PP3.09 Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) ...
Orlando, Florida (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract #290 Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment ...
Zürich, Switzerland (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, on World Haemophilia Day, Novo Nordisk announces that the grant scheme to support and encourage research projects focused on the psychosocial issues faced by people with haemophilia is open for ...
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Oral Presentation# OR36-1 Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at ...
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #689-P Findings from a clinical trial comparing Victoza® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin ...
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #OR15-1 Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide ...
Glasgow, Scotland (ots/PRNewswire) - This material is intended for European and UK medical media only. For journalistic assessment and preparation before publication. New findings show that Xultophy® (insulin degludec/liraglutide; IDegLira), the first once-daily combination of a long-acting basal insulin ...
Vancouver, British Columbia (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. Abstracts 0336-P, 0337-P, 0338-P New analyses demonstrate that ...
Vancouver, Canada (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. Results from the Perceptions of Control (POC) study showed that people with type ...
Vancouver, Canada (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. Abstracts: 0720-P, 0721-P, 1074-P, 0956-P New data from four analyses[1],[2],[3],[4] demonstrate that post-meal hyperglycaemia (when ...
Vancouver, Canada (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. New findings from a network meta-analysis show that treatment with Victoza® (liraglutide) provides a greater HbA1c reduction and an ...
Milan (ots/PRNewswire) - Abstract: PDB54 B20 New findings from a health economics and outcomes research (HEOR) analysis demonstrated that Victoza® (liraglutide) 1.2 mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to lixisenatide and is cost-saving compared to exenatide.[1] ...
Stockholm, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract #75 Findings from a head-to-head trial comparing Victoza(R) (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a ...
Stockholm, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication Abstract #645 Today, new data from a post-hoc analysis of the phase 3a SCALE(TM) clinical development programme were presented at the 51st European Association ...
Stockholm (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the ...
Stockholm, Sweden (ots/PRNewswire) - Results presented today at the European Association for the Study of Diabetes (EASD) showed that increased awareness about how patients' and physicians' perceptions of control differ, could benefit physician-patient communication and improve diabetes management.[1] New findings ...
Stockholm, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. New findings from the DUAL(TM) V phase 3b clinical trial showed greater improvements in treatment-related satisfaction and patient-reported physical ...